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Prematurity	  is	  not	  a	  new	  phenomena.	  	  Advances	  in	  medical	  technology	  has	  
allowed	  for	  increased	  survival	  of	  the	  smallest	  infants	  with	  the	  earliest	  age	  being	  22	  
to	  23	  weeks	  gestation.	  	  Despite	  the	  medical	  advances,	  these	  tiny	  infants	  are	  at	  risk	  
for	  numerous	  postnatal	  complications.	  	  Complications	  of	  prematurity	  can	  affect	  
many	  body	  systems	  and	  include	  infection,	  intraventricular	  hemorrhage,	  chronic	  
lung	  disease,	  osteopenia,	  retinopathy	  of	  prematurity	  and	  necrotizing	  enterocolitis	  
(Angert,	  2009).	  	  Prevention	  is	  crucial	  in	  all	  these	  disease	  states,	  in	  particular	  the	  use	  
of	  probiotics	  in	  preventing	  necrotizing	  enterocolitis.	  	  Bifidobacteria	  and	  lactobacilli	  
are	  the	  common	  intestinal	  flora	  found	  in	  term,	  breastfed	  infants.	  	  Preterm	  infants	  
lack	  this	  normal	  flora.	  	  	  Probiotics	  such	  as	  Bifidobacteria	  and	  Lactobacillus	  are	  live	  
microbial	  supplements	  that	  	  are	  intended	  to	  colonize	  and	  normalize	  the	  intestines	  of	  
premature	  infants	  in	  an	  effort	  to	  prevent	  the	  overgrowth	  of	  pathogenic	  organisms	  
which	  can	  lead	  to	  necrotizing	  enterocolitis.	  	  	  	  “The	  evidence	  that	  probiotics	  reduce	  
mortality	  rates	  is	  as	  conclusive	  as	  that	  for	  surfactant	  for	  respiratory	  distress	  
syndrome,	  cooling	  for	  hypoxic	  ischemic	  encephalopathy,	  or	  antenatal	  
corticosteroids	  for	  threatened	  preterm	  labor”	  (Tarnow-Mordi, Wilkinson, Trivedi, & 
Brok, 2010, p. 1069). 	  
	  
Definition	  and	  Description	  of	  the	  Disease	  
Necrotizing enterocolitis (NEC) is a common gastrointestinal emergency that 
affects as many as 14% of very low birth weight (VLBW) preterm infants in the neonatal 
intensive care unit (NICU) (Lin et al., 2008).   The mortality rate for infants diagnosed 
PROBIOTICS	  AND	  NEC	  
	  
3	  
with NEC is 20-50% with higher mortality rates corresponding to greater bowel 
involvement (Gibbins, Maddalena, & Golec, 2008).  The exact cause of NEC remains 
unknown but many factors are believed to contribute to NEC.  These include prematurity, 
enteral feeding, intestinal ischemia and bacterial colonization (Lin et al., 2008).   The 
incidence of NEC is inversely related to birth weight and gestation.  Medical 
management of NEC is aimed at preventing progression.  If NEC is suspected, enteral 
feeds are stopped, IV fluids are started, nasogastric decompression is initiated, and IV 
antibiotics started.  Lab values and serial abdominal x-rays are conducted.  In some cases 
NEC progresses despite medical management and surgery is needed for peritoneal 
drainage or bowel resection (Ladd and Ngo, 2009). 
 Four risk factors are believed to contribute to NEC.  The first risk factor is 
prematurity.  NEC occurs in 5-10% of all infants less than 1500 grams at birth.  The 
second risk factor is enteral feedings.  Although NEC occurs weeks after feedings are 
started, it usually occurs when full feeding amounts are achieved.  Infection is the next 
risk factor although no specific bacterium has been pinpointed.  Normal intestinal flora 
consisting of lactobacilli and bifidobacerium are not evident in preterm infants until three 
to four weeks after birth.  This lack of normal flora is attributed to late start of enteral 
feedings and use of broad-spectrum antibiotics.  Mucosal injury or ischemia is the fourth 
risk factor but it is unclear if ischemia is the cause of NEC as in asphyxia or the result of 
NEC from the mucosal inflammation (Gibbs, Lin and Holzman (2007).  
Hammerman and Kaplan (2006) explain the microflora of infant intestines and 
how probiotics can help with restoring normal flora and thereby reduce the incidence of 
NEC.  A newborn gut is sterile until birth.  A normal, full term, breastfed newborn will 
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colonize a variety of intestinal bacteria with bifidobacteria being the dominant one.  The 
preterm infant has a much different colonization due to the delayed start of feedings and 
use of broad-spectrum antibiotics, with a smaller number of bacterial strains.  Those that 
are present are usually pathogenic and include klebsiella, enterobacter and clostridium 
organisms.  The appearance of the normal bifidobacteria usually does not occur in the 
preterm infants until 2-3 weeks after birth, making the preterm infant more susceptible to 
NEC.   Underwood, et al. concluded probiotics did increase bifidobacteria in the preterm 
infants (2009).  In addition, many probiotic clinical trials have been conducted outside 
the United States, which have shown a significant decrease in the incidence of NEC in 
preterm infants greater than 1000 grams (Ladd and Ngo, 2009).   
The sequelae of infants who survive NEC include short-gut syndrome, poor 
growth, prolonged initial hospitalization, multiple re-hospitalizations and poor long-term 
neurodevelopment (Martin & Walker, 2008).  Preventing NEC is instrumental in 
decreasing the morbidity and mortality from this gastrointestinal emergency.  Evidence 
based studies have shown a decrease in NEC in breast fed babies and conservative 
trophic feedings.  Other experimental methods of prevention include antenatal steroids, 
enteral antibiotics, and probiotics (Ladd and Ngo, 2009).  The use of probiotics is an 
inexpensive, safe and effective treatment for the prevention of NEC.     
	  
Current	  Review	  of	  Evidence-­Based	  Literature	  
The literature was searched for information about the use of probiotics in the 
prevention of necrotizing enterocolitis.  An electronic search of CINAHL and MEDLINE 
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databases was performed using keywords necrotizing enterocolitis and probiotics.   The 
time frame searched was from 2000 to 2010.   
Hammerman and Kaplan (2006) compare four clinical trials that used probiotics 
in preterm infants and evaluated the incidence of NEC.  Three out of the four studies 
demonstrated a decreased incidence of NEC with relative risk: 0.395 (95% CI, 0.279-
0.559) and P < 0.001.  One of the four studies showed a decrease in mortality from 
probiotic use.  The overall result was not significant with a relative risk of 0.896 (95% 
CI, 0.709-1.132) and P = 0.388.  None of the four studies showed a significant increase or 
decrease in sepsis with overall relative risk: 1.02 (95% CI, 0.801-1.302) and P = 0.913. 
Finally the authors concluded probiotics are a safe, noninvasive, disease-preventing 
option that should be considered a treatment option in neonatology.  “Their efficacy in 
preventing NEC renders them a most attractive addition to the clinical armamentarium.  
To date, very few other strategies have been proven definitively to be efficacious in 
decreasing the incidence of NEC (Hammerman and Kaplan, 2006, p. 282).  
 In the summary of their multicenter randomized controlled trial, Lin et al. begin 
with presenting the problem of NEC and the possible contributing factors. The authors 
explain that previous clinical trials found probiotics decreased the incidence of NEC but 
these trials failed to define optimal strains, timing, dosage and duration.  The hypothesis 
was clearly stated.  The method was a prospective, randomized, masked, controlled trial 
involving seven NICU’s in Taiwan.  The population included 443 preterm infants with 
birth weight less than 1500 grams and they were randomized to a group that received 
Infloran, a probiotic, with breast milk twice per day or a group that received breast milk 
alone.  Inclusion and exclusion criteria were defined.  Parental consent was obtained and 
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approval was given by the IRB before initiation of the study.  Death or NEC occurred in 
4 out of 217 infants in the study group and 20 out of 217 in the control group.  The NNT 
to prevent one case of NEC was 20 infants and the NNT to prevent 1 death or case of 
NEC was 14.  A post-hoc analysis was done to evaluate for bias or center variations. 
Final conclusions support the use of the probiotics containing B bifidum and L 
acidophilus for six weeks to decrease the incidence of NEC in VLBW preterm infants.  
 Underwood, et al. explain how the preterm infant lacks the important normal 
bacteria that are needed for growth and good health.  Discussion of the variety of 
outcomes from previous probiotic studies reveals that the differences occurred based on 
the infants gestational age and the type of probiotic used.  The team of researchers 
investigated three groups, two of the groups received two different commercially 
produced probiotics and the third group received a placebo.  This was a double blind, 
placebo-controlled, randomized study that evaluated the effect of probiotics on weight 
gain, fecal microbiota and fecal short-chain fatty acid content of the preterm population.  
The study was IRB approved and parental consent was obtained.  Inclusion and exclusion 
criteria were identified.  The data collection and analysis was scientifically thorough.  
The first result of the study revealed the actual make up of the probiotics differed from 
their advertised labels.  The study revealed no significant difference in weight gain 
between the placebo and intervention groups.  Final stool samples revealed a significant 
difference in the bacteria between the intervention and placebo groups.  The intervention 
groups showed a large colonization of bifidobacteria, similar to a term breast-fed infant, 
whereas the placebo group showed low counts of bifidobacteria, typical of a preterm 
infant.  This was the first study in the United States to compare two probiotic products to 
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a placebo.  The study revealed different make up in the advertised versus actual 
compositions of the probiotics.  Although the study revealed advantageous differences in 
the fecal bacteria composition between the intervention and control groups, it also 
revealed the issue of purity of probiotics and questioned their use in the vulnerable 
preterm population.  Finally the authors recommended more large, multi-centered trials 
before the widespread use of probiotics is implemented in the preterm population.  
  
Final analysis revealed two meta-analysis articles.  The first is Probiotics for 
Prevention of Necrotizing Enterocolitis in Preterm Infants (2008).  In this Cochran 
review AlFaleh and Bassler compare probiotic versus placebo or no treatment in the 
prevention of NEC and/or sepsis in preterm infants.  Standard Cochrane search strategy 
was used and only quasi-randomized or randomized trials were included.  Inclusion 
criteria was preterm infants less than 37 weeks and/or less than 2500 grams.  Nine trials, 
consisting of 1425 infants were included.  Specific data related to VLBW infants could 
not be extrapolated.  The meta-analysis revealed probiotics decreased the incidence of 
stage II or greater NEC with a relative risk of 0.32 (95% CI, 0.17-0.60.  Probiotics also 
reduced mortality from NEC with the relative risk 0.43 (95% CI, 0.25-0.75).  No 
significant change in sepsis incidence was noted, relative risk 0.93 (95% CI, 0.70-1.19). 
Final analysis did reveal that probiotics did significantly reduce the incidence of severe 
NEC and a practice change was recommended for preterm infants greater than 1000 
grams.   
 The second article is Updated Meta-analysis of Probiotics for Preventing 
Necrotizing Enterocolitis in Preterm Neonates (2010) by Deshpand, Rao, Patole, & 
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Bulsara.  Cochrane Central register, Medline, Embase and Cinahl databases were 
searched with a total of eleven (N = 2176) trials included in the meta-analysis.  A greater 
number of infants in the control group (no probiotics) developed NEC compared with the 
group that received the probiotics, with a relative risk: 0.35 (95% CI, 0.23-0.55) and P < 
0.00001.  The number need to treat (NNT) to prevent one case of NEC was 25.  Probiotic 
use did not show a significant decrease in sepsis, with relative risk 0.98 (95% CI, 0.81-
1.18) and P = 0.80.  Probiotic use also showed a significant decrease in mortality, with 
relative risk 0.42 (95% CI, 0.29-0.62 and P < 0.00001.  NNT to prevent 1 death was 20.  
A sensitivity analysis of five trials (N = 1717) revealed decreased NEC in the probiotic 
group with relative risk of 0.29 (95% CI, 0.17 – 0.59) and P < 0.00001 and a decreased 
mortality with relative risk 0.39 (95% CI, 0.25-0.59) and P < 0.00001.  All the included 
trials had a Jadad quality score of =/> 3.  “Overall, the results of our updated systemic 
review and meta-analysis (11 good quality RCT’s and N = 2176) confirm the dramatic 
benefits of probiotic supplements in reducing the risk for death and for definite NEC in 
preterm VLBW neonates”, with VLBW infants defined as less than 1500 grams.  
(Deshpand, et al, 2010, p. 925).  
  
Diagnosing NEC 
Necrotizing enterocolitis is an inflammatory bowel disease that mainly affects 
preterm infants.  The exact pathophysiology of NEC remains unknown but it is thought to 
be a multi-factorial process.  Intestinal ischemia with reperfusion, bacteria in the gut and 
enteral feedings can activate inflammatory mediators, which are thought to contribute to 
the pathophysiology of NEC.  Once the inflammatory mediators are activated, the 
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premature infant is unable to modulate this response.  This is the common pathway for 
the disease, which can lead to bowel injury and or death.  Although the exact cause of 
NEC remains unknown, the key to decreasing the incidence of this catastrophic disease is 
prevention.  Trials on different feeding strategies have been investigated, comparing 
earlier feeding introduction to delayed feeding.  Neither feeding plan proved to decrease 
the incidence of NEC.  Other randomized controlled trials have investigated the use of 
IGA and IGG in the prevention of NEC with no significant reduction noted.   
Prophylactic antibiotics have also been considered but the risks outweigh the benefits.  
Only three preventative treatment strategies have been shown to give some protection 
against NEC and are the only promising preventative measures in the prevention of NEC 
(Gibbins, Maddalena and Golec, 2008): 
• The exclusive use of maternal breast milk  
• Standardized feeding protocols, specifically advancing feedings cautiously 
by a priori decisions not just early versus delayed feeding  
• Prophylactic probiotics  
 The clinical presentation of NEC can be very non-specific and insidious or it can 
present as a catastrophic emergency leading to shock and possibly death in a short time 
period.  The signs and symptoms include apnea, bradycardia, oxygen desaturation, 
lethargy, irritability, temperature instability, abdominal distention, abdominal tenderness, 
absent bowel sounds, feeding intolerance, abdominal wall cellulitis, blood in the stool, 
emesis, and increased gastric residuals.  Diagnostic laboratory abnormalities include 
metabolic acidosis, thrombocytopenia, leucopenia, leukocytosis with increased band 
cells, glucose instability, hyponatremia, coagulation abnormalities, and increased C-
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reactive protein.  Finally radiographic abnormalities include intestinal dilatation, presence 
of fixed loop of the dilated bowel, thickening of the intestinal wall, ascites, air in the 
portal venous system pneumatosis intestinalis, which is the accumulation of hydrogen gas 
in the bowel wall by fermentation of carbohydrates by gas-producing organisms and 
pneumopeironeum (Thompson and Bizzarro, 2008). 
 A staging system for classifying NEC was introduced by Bell and colleagues in 
1978.  This staging system breaks NEC down into 3 stages. Stage I is suspected NEC and 
includes the symptoms of temperature instability, apnea and bradycardia, lethargy, 
increased gastric residuals, mild abdominal distention, emesis, and bloody stools.  
Radiographic findings would show normal or mild intestinal dilatation or mild ileus.   
Stage II is Definitive NEC and includes all the symptoms of stage one and in addition 
there is an absence of bowel sounds, abdominal tenderness, mild metabolic acidosis and 
mild thrombocytopenia.   Radiographic studies show intestinal dilatation, ileus or 
pneumatosis intestinalis.  Finally stage 3 NEC is the most severe and includes all the 
symptoms of stage I and II and in addition there is severe apnea and bradycardia, 
respiratory and metabolic acidosis, neutropenia, thrombocytopenia and disseminated 
intravascular coagulation (Gibbins, et al, 2008).   Bell’s NEC classification system is 
further divided in to class A and B in each stage as listed below in Table 1 (Hughes, Baez 










Stage	  I:	  suspected	  NEC	  
A.	  Systemic	  signs	  are	  nonspecific,	  including	  apnea,	  bradycardia,	  lethargy,	  and	  temperature	  
instability.	  
B.	  Intestinal	  finding	  include	  feeding	  intolerance,	  recurrent	  gastric	  residuals,	  and	  guaiac-­‐positive	  
stools.	  
C.	  Radiographic	  findings	  are	  normal	  or	  nonspecific.	  
In	  stage	  IB,	  the	  diagnosis	  is	  the	  same	  as	  stage	  IA,	  with	  the	  addition	  of	  grossly	  bloody	  stool.	  
	  
Stage	  II	  is	  the	  definite	  diagnosis	  of	  NEC.	  	  
Stage	  IIA:	  mild	  NEC	  
A.	  Systemic	  signs	  are	  similar	  to	  those	  in	  stage	  I.	  	  
B.	  Intestinal	  findings	  include	  prominent	  abdominal	  distention	  with	  or	  without	  tenderness,	  
absent	  bowel	  sounds,	  and	  gross	  blood	  in	  stools.	  	  
C.	  Radiographic	  findings	  include	  ileus,	  with	  dilated	  loops	  with	  focal	  areas	  of	  pneumatosis	  
intestinalis.	  	  
	  
Stage	  IIB:	  moderate	  NEC	  
A.	  System	  signs	  include	  stage	  I	  signs	  plus	  mild	  acidosis	  and	  thrombocytopenia.	  
B.	  Intestinal	  findings	  include	  increasing	  distention,	  abdominal	  wall	  edema,	  and	  tenderness	  with	  
or	  without	  a	  palpable	  mass.	  
C.	  Radiographic	  findings	  include	  extensive	  pneumatosis	  and	  early	  ascites	  intrahepatic	  portal	  
venous	  gas	  may	  be	  present.	  
	  
Stage	  III:	  advanced	  NEC	  
Stage	  IIIA:	  advanced	  NEC	  
A.	  Systemic	  findings	  include	  respiratory	  and	  metabolic	  acidosis,	  assisted	  ventilation	  for	  apnea,	  
decreasing	  blood	  pressure	  and	  urine	  output,	  neutropenia,	  and	  coagulopathy.	  
B.	  Intestinal	  findings	  include	  spreading	  edema,	  erythema,	  or	  discoloration,	  and	  induration	  of	  the	  
abdominal	  wall.	  	  
C.	  Radiographic	  findings	  include	  prominent	  ascites,	  paucity	  of	  bowel	  gas,	  and	  possibly	  a	  
persistent	  sentinel	  loop.	  
	  
Stage	  IIIB:	  advanced	  NEC	  
A.	  Systemic	  findings	  reveal	  generalized	  edema	  deteriorating	  vital	  signs	  and	  laboratory	  indices,	  
refractory	  hypotension,	  shock	  syndrome,	  disseminated	  intravascular	  coagulation,	  and	  
electrolyte	  imbalance.	  	  
B.	  Intestinal	  findings	  reveal	  a	  tense,	  discolored	  abdomen	  and	  ascites.	  	  
C.	  Radiographic	  findings	  commonly	  show	  absent	  bowel	  gas	  and	  often	  evidence	  of	  
intraperitoneal	  free	  air.	  





Treatment and Prevention of NEC 
 
 Treatment of NEC is divided into two categories: medical and surgical 
interventions, which is based on the degree of disease as categorized by the Bell staging 
system. Medical treatment entails resting the bowel by stopping all enteral feedings, 
placing a nasogastric tube to low intermittent suction, and initiation of intravenous fluids 
usually total parenteral nutrition with intravenous lipids.  A full septic workup including 
blood culture, urine culture and cerebral spinal fluid culture should be performed to 
identify the bacteria that may have caused NEC.  After cultures are obtained, intravenous 
antibiotics must be initiated and would include ampicillin and vancomycin for gram-
positive organism coverage, gentamicin and cefotaxime for gram-negative organisms, 
and metronidazole and clindamycin for anaerobic organisms (Thompson and Bizzarro, 
2008).  Bowel rest and antibiotics should continue for 7-14 days and antibiotics adjusted 
based on cultures and sensitivities.  Finally, serial radiographic studies must be performed 
to monitor disease status.  Surgical intervention is usually indicated if progression of 
disease has advanced to Bell’s stage III.  Exploratory laporatomy is done to identify and 
remove and necrotic bowel.   
 Prevention is instrumental to decreasing the incidence of NEC.  There are five 
interventions that have proven to be instrumental in decreasing NEC.  These are antenatal 
corticosteroids, trophic feedings, breast milk, oral antibiotics and most recently probiotics 
(Thompson and Bizzarro, 2008).   Gibbins, Maddalena and Golec found that only three 
measures were proven to decrease the incidence of NEC and these are breast milk, 
standardized feeding protocols and probiotics (2008).  Probiotics and breast milk are the 
two prevention measures found in both investigations.  
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 “Probiotics are defined as live microbial supplements that colonize the intestine 
and provide benefit to the host.  Benefits of probiotics are normalization of intestinal 
mucosal barrier function, protection of the gut from pathogens, decreased inflammatory 
processes, increased anti-inflammatory cytokines, improved enteral nutrition, and 
reduced infection rates secondary to bacterial translocation” (Gibbins et al, p. 147, 2009).  
Probiotics are thought to prevent NEC by encouraging competitive colonization, 
producing organic acids that decrease pH and inhibit growth of pathogens, increasing 
peristalsis, modulating immune response, producing anti-inflammatory cytokines, 
competing for pathogen binding and receptor sites, producing bactericocins, influencing 
intestinal mucosa to enhance mucin production, stimulating IgA production and 
enhancing enteral nutrition (Hughes, et al, 2009).  The research that has been conducted 
demonstrates that the use of probiotics does reduce the incidence of NEC.   
Patient and Family Counseling 
 An infant diagnosed with NEC can be a very scary situation for the parents of the 
infant.  Parents should immediately be informed of their infant’s change in status and the 
results of preliminary tests and findings.  Parents need to be involved in the decision-
making process and be allowed to consider all the options along the care continuum.  
When prognosis is grim and treatment is futile, parents need to be given some time to 
come to terms with the challenging diagnosis.  “Referred to as ‘the temporal gap,’ parents 
are often several days behind caregivers in grasping condition and prognosis and have 
little or no experience on which to draw upon” (Gibbins, et al, p.150, 2009).  In turn, 
parents will be left to make some difficult decisions, which need to be supported, and 
family-centered care must be central to the care of the infant.  
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Patient and Family Education 
 Both family education and family counseling must be included in the plan of care.  
Education is giving the family the information in a clear and concise manner.  Counseling 
is giving families the emotional support to deal with the new diagnosis.  NEC can be a 
potentially fatal diagnosis for a preterm infant.  Early parent education about the 
complications of prematurity should include prevention of NEC with the use of probiotic 
supplementation in preterm infants. Education and prevention are key components to 
eliminating the problem of necrotizing enterocolitis in the preterm infant population.  
Caring for an infant with NEC involves a multi-system approach.  Family 
education is one are that can sometimes be forgotten but is very important in the care of 
the infant with NEC.  First, parents need to be informed immediately in the infant’s 
change in status.  Informing parents of the preliminary diagnosis including possible 
outcomes and options.   The use of Bell’s NEC classification system is a helpful tool in 
visually detailing the stages of NEC.  The family needs to be included in the consultation 
process with specialists.  The family will need time to come to terms with the new, 
potentially life-threatening diagnosis.  Finally the family needs to be given all the options 
along the continuum of care.  
 
Conclusion 
Necrotizing enterocolitis is a devastating condition that still has no exact etiology 
and no specific therapy.  Prematurity is a predisposing risk factor for NEC.  Preterm 
infants are known to have altered intestinal flora.  Probiotics are promising therapy in 
establishing normal intestinal flora in the preterm infant.  The clinical trials to date have 
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shown some benefit in the use of probiotics for the prevention of NEC in preterm infants.  
The problem is that each clinical trial has treated different populations, used different 
outcome measures and used different probiotic organisms.  FDA approval of probiotic 
preparations that have proven to decrease the incidence of NEC could significantly help 
to reduce this devastating disease.  Probiotics have the potential to become a clinical 
breakthrough in the prevention of necrotizing enterocolitis in the preterm infant.  
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